Evidence map›Paper›PMID 42479341›Full record

ArticleDrug delivery and translational research2026

Platelet membrane-fusing MSC-derived apoptotic extracellular vesicles enhanced cardiac repair after ischemia/reperfusion injury.

Zhifeng Song, Fangshun Tan, Yu Jiang, Shuo Wang, ZhiYao Wei, Miao Yu, Hongrui Yu, YanXia Tu, Liaoming He, Weixian Yang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhifeng Song *Center for Coronary Heart Disease, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Fangshun Tan *Center for Coronary Heart Disease, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yu Jiang *Cardiac Arrhythmia Center, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shuo WangBeijing Key Laboratory of Preclinical Research and Evaluation for Cardiovascular Implant Materials, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Animal Experimental Center of Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 102300, China.
ZhiYao WeiCenter for Coronary Heart Disease, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Miao YuCenter for Coronary Heart Disease, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hongrui YuPulmonary Vascular Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100037, China.
YanXia TuDepartment of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, 167 Beilishi Road, Xi Cheng District, Beijing, 100037, China.
Liaoming HeDepartment of Cardiovascular Surgery, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Weixian YangCenter for Coronary Heart Disease, Department of Cardiology, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. fwywx66@126.com.
Haiyan QianCenter for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China. ahqhy712@163.com.ORCID http://orcid.org/0000-0003-4422-6127

Funding

Beijing Anzhen Hospital High Level Research Funding 2024AZB1004Foundation for Clinical and Translational Medical Research, Central Public Welfare Research of Chinese Academy of Medical Sciences 2022-I2M-C&T-B-050Foundation for Clinical research of central high-level hospitals 2023-GSP-GG-13, 2023-GSP-GG-32National Natural Science Foundation of China No: 82192902Natural Science Foundation of Beijing Municipality 7222139Parallel Project of Excellent Clinical Research Program in Research Wards of Beijing BRWEP2024W012060111the National Key Research and Development Program of China 2022YFC2009700, 2022YFC2009706
6 · The paper itself

Abstract

Myocardial ischemia/reperfusion injury (I/RI) is a common complication following percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI). Mesenchymal stem cell-derived apoptotic vesicles (MSC-apoVs) seem to be a promising cell-free therapy for alleviating cardiac I/RI, but their therapeutic efficiency is hindered by insufficient targeting capability in vivo. The present study aims to explore the platelet membrane-modified apoVs (P-apoVs), utilizing the nature affinity of platelets for apoV delivery to the injured vascular and myocardial sites. P-apoVs exhibited excellent physicochemical properties, and microRNA (miRNA)-sequencing showed that the extrusion process had no detrimental effects on the content and distribution of miRNAs. Compared to non-modified apoVs, the cellular uptake of P-apoVs was greatly enhanced in bone marrow-derived macrophages (BMDMs), human umbilical vein endothelial cells (HUVECs) stressed by oxygen glucose deprivation/reperfusion (OGD/R) and neonatal rat cardiomyocytes (NRCMs) stressed by OGD/R. Functionally, P-apoVs inhibited the apoptosis of OGD/R NRCMs, promoted BMDM polarization toward M2 phenotype, as well as enhanced HUVEC migration and tube formation in vitro. In the myocardial I/RI model, P-apoVs preferentially accumulated in the injured myocardial sites and attenuate cardiac modeling after I/RI without systemic toxicity. In conclusion, this engineering platelet-modified apoVs shows potential as a therapeutic strategy for myocardial I/RI.

Indexed as

Apoptotic vesiclesMyocardial ischemia/reperfusion injuryPlatelet-mimeticTargeted delivery

Identifiers

PMID42479341

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.